Given that NPM1 is already a therapeutic target in hematopoietic cancers, our findings suggest that targeting NPM1 could also benefit patients with WNT-driven solid tumors, such as KRAS-mutant CRC and hepatic cancers, which remain challenging to treat. This evidence concerns the gene NPM1 and hematopoietic and lymphoid cell neoplasm.